Harnessing genetic crosses to understand malaria drug resistance
Official title: Harnessing the Power of Experimental Genetic Crosses to Probe Drug Resistance in Malaria
Funded at University of Notre Dame · NIH-11355523 · Data updated 2026-11-12
In this project, researchers are studying how malaria becomes resistant to drugs by using genetic crosses and sharing findings openly with researchers worldwide.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Notre Dame NIH-funded |
| Lab location | 1 site (Notre Dame, United States) |
| Project start | August 1, 2017 |
| Project end | April 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $255,956 |
| NIH project number | 5P01AI127338-08 |
| Project ID | NIH-11355523 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not a direct patient study; focus is on malaria biology and data sharing to benefit patients through improved treatments.
✕Less likely to help
No immediate patient participation or direct clinical testing is described.
What this research studies
This program project includes creating and analyzing genetic crosses to uncover mechanisms behind malaria drug resistance. It emphasizes collaboration across three sites, centralized data sharing, and clear communication to accelerate discovery. The Admin Core will coordinate administration, data/material sharing, and progress reporting to ensure the team works as a cohesive unit while making resources accessible to others in the malaria research community.
Why it matters
Potential benefit: If successful, findings could lead to better understanding of resistance mechanisms and inform new strategies to prevent or overcome drug resistance in malaria.
How similar studies have gone: Previous collaborative cores have improved data sharing and coordination, supporting larger, multi-site malaria research.
Where this research is happening
-
University of Notre Dame
Notre Dame, United States Active
Researchers
- Principal investigator: Ferdig, Michael T — University of Notre Dame
- Study coordinator: Ferdig, Michael T
Related research
Other NIH-funded projects on the same topics.
-
Digital malaria surveillance in Ethiopia to improve outbreak detection
A collaboration to add a malaria-specific digital module to an existing surveillance system in Africa to help detect and respond to outbreaks faster.
-
Cross-sector partnership uses digital malaria surveillance in Ethiopia
A US-based team will adapt and test a digital malaria surveillance module in SORMAS to help detect and respond to malaria outbreaks in Ethiopia.
-
Malaria control project in Western Kenya to reduce illness and deaths
A large, multi-year effort in western Kenya will help track malaria spread and test ways to prevent transmission so fewer people get sick or die.
-
Optimizing tafenoquine dose to prevent relapse of vivax malaria in Asia
A study tests the best tafenoquine dose to prevent P. vivax malaria relapse in people in East Asia and Oceania.
-
Optimizing tafenoquine dose to prevent P. vivax malaria relapses in Asia
A study to find the best single-dose tafenoquine amount to prevent relapse of P. vivax malaria in people in East Asia and Oceania.
-
Severe malaria and brain risk in children
This grant studies how severe malaria in young children can affect brain development and long-term thinking and behavior, with a focus on kids in Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.